Overview

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Collaborator:
National Cancer Institute (NCI)
Treatments:
Immunotoxin HA22